2-Ethoxy-1,3-Thiazole

In the formulation of thermally processed savory flavors, 2-ethoxy-1,3-thiazole (CAS 15679-19-3) functions as a high-impact character impactor conferring roasted, sulfury, and nutty top-notes indistinguishable from naturally occurring Maillard-generated thiazoles. The compound is listed under FEMA 3694 and evaluated by JECFA as a flavoring substance with no safety concern at current estimated dietary intake levels. In compounded coffee flavor oils, the ingredient is typically pre-dispersed as a 1% (w/w) solution in triacetin or benzyl alcohol to facilitate homogeneous dosing before being blended into a carrier medium of fractionated coconut oil. In aqueous beverage applications requiring transparency, a micellar solubilization system utilizing polysorbate 80 at a surfactant-to-flavor ratio of 3:1 maintains physical stability for a shelf life exceeding 12 months at ambient storage. Finished food product addition rates vary by category, with sensory threshold detection reliably determined via ASTM E679 forced-choice ascending concentration series methodology, yielding an orthonasal best-estimate threshold in water of 0.08 ppb. The FEMA survey of usage levels, reproduced below, demonstrates the exceptional potency of this compound across multiple food matrices.

Direct addition of neat 2-ethoxy-1,3-thiazole to dry-blended seasoning premixes intended for high-shear, high-temperature twin-screw extrusion (L/D ratio 32:1, barrel temperature profile 120–170 °C) results in volatile losses exceeding 60% unless the aroma chemical is first plated onto a porous carrier such as silicon dioxide (precipitated silica, oil absorption capacity 250 mL/100 g) or encapsulated via spray drying. A production-scale spray-drying encapsulation protocol employs a Niro FSD Minor plant with a rotary atomizer wheel speed of 18,000 rpm, inlet air temperature of 180 °C, and outlet temperature of 85 °C. The feed emulsion consists of gum arabic (Acacia senegal) and maltodextrin (DE 10) at a wall-material-to-core ratio of 4:1, homogenized in a two-stage high-pressure homogenizer (APV Gaulin, 250/50 bar). The resulting free-flowing powder exhibits a glass transition temperature (Tg) of 42 °C as measured by differential scanning calorimetry (ISO 11357-2:2020), which prevents caking during storage in tropical climates, and retains 92% of the nominal volatile payload after 6 months in aluminum trilaminate foil pouches under nitrogen headspace. Regulators confirm the substance’s status as a synthetically derived flavoring substance permitted in the EU under Regulation (EC) No 1334/2008 and in the United States under FDA 21 CFR §172.515 as an adjuvant and flavoring agent. An operational restriction in high-acid retorted products (pH ≤3.5) is the acid-catalyzed hydrolysis of the ethoxy ether linkage, which generates ethanol and 2-hydroxythiazole, the latter undergoing rapid tautomerization to thiazolidin-2-one, a species with a markedly lower flavor potency. This degradation becomes kinetically significant above 121 °C and mandates immediate post-retort injection of the flavor solution via an aseptic dosing skid following HTST sterilization of the flavor premix.

Can the Ethoxy Group Serve as a Leaving Group in Nucleophilic Amination for Cephalosporin Intermediates?

Within the current good manufacturing practice (cGMP) synthesis of third-generation cephalosporin antibiotics, the construction of the 2-aminothiazole pharmacophore remains a critical bottleneck due to the genotoxic impurities associated with traditional halogenated precursors. 2-Ethoxy-1,3-thiazole provides a halogen-free entry into this scaffold through a nucleophilic aromatic substitution mechanism, wherein the ethoxy moiety acts as a leaving group toward aqueous ammonia under solvothermal conditions. An optimized pilot-scale procedure charges a 50 L Hastelloy C-276 autoclave with 2-ethoxy-1,3-thiazole (1.0 mol), 25% aqueous ammonia solution (5.0 mol), and absolute ethanol (2.5 L) as a co-solvent to enhance mutual solubility. The sealed vessel is heated to an internal temperature of 150 °C over 90 min, generating an autogenous pressure of 8–10 bar, and maintained under continuous stirring (pitched-blade impeller, 300 rpm) for 10 h. Post-reaction, the crude mixture is concentrated under reduced pressure (50 mbar, 45 °C), and the residue is recrystallized from toluene/hexane (1:3 v/v) to afford 2-aminothiazole as off-white needles with a purity of 99.4% (HPLC area%, UV detection at 254 nm) and a typical isolated yield of 86%. This intermediate is directly converted to (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid, the side-chain moiety of cefdinir, cefixime, and cefpodoxime proxetil, by established multi-step protocols. Residual ethanol in the final API must conform to the ICH Q3C (R8) guideline limit of 5,000 ppm (Class 3 solvent), monitored by headspace GC-FID per USP <467>. A distinct process advantage of the ethoxy leaving group over the conventional 2-chloro route is the avoidance of ethylene dichloride as a reaction solvent and the elimination of trace vinyl chloride carryover, which would trigger a Positive In Silico (Q)SAR alert for OECD 490 in vitro gene mutation assays. The principal process impurity, identified as 2,2′-iminobis(thiazole) formed from a secondary condensation, is controlled to below 0.15% through careful regulation of the ammonia stoichiometry and a slow linear cooling crystallization ramp of 0.5 K/min from 55 °C to 5 °C. In continuous flow chemistry equipment (Corning Advanced-Flow Reactor G1 module, SiC plates), the same transformation has been demonstrated with a residence time of 25 min at 170 °C under 18 bar back-pressure, yielding 92% conversion and an STY of 1.8 kg/L/h, though full industrial adoption remains under evaluation due to the precipitation of the product within the reactor channels at prolonged run times exceeding 8 h.

Phosphorus Oxychloride-Mediated Conversion to 2-Chloro-1,3-Thiazole for Commercial Neonicotinoid Production Lines

Conversion of the ethoxy substituent to chlorine is the pivotal activation step en route to the 2-chloro-5-methylthiazole intermediate embedded in the structure of clothianidin and thiamethoxam insecticides. In a glass-lined jacketed reactor (Pfaudler, 1,000 L), 2-ethoxy-1,3-thiazole (98% purity, 100 kg) is combined with phosphorus oxychloride (1.25 molar equivalents) and catalytic N,N-dimethylformamide (0.05 molar equivalents). The heterogeneous mixture is gradually heated to 95 °C over 60 min, at which point HCl gas evolution commences and is scrubbed through a packed-bed water absorber. The reaction mass is held at 95–100 °C for 4 h until GC analysis (HP-5 capillary column, 30 m × 0.32 mm, FID) indicates consumption of starting material to below 0.5%. After cooling to 25 °C, the reaction is quenched by slow transfer onto crushed ice (500 kg) in a Hastelloy quench tank, maintaining the quench temperature below 10 °C to suppress exthothermic hydrolysis of residual POCl₃. The aqueous phase is extracted with dichloromethane (3 × 80 L), and the combined organic layers are washed with 10% sodium carbonate solution until neutrality. Consecutive fractional distillation under vacuum (reflux ratio 3:1) using a Sulzer structured packing column (HETP 0.3 m) collects 2-chloro-1,3-thiazole at a head temperature of 42–44 °C at 15 mbar as a water-white liquid with a refractive index n₂₀ᴰ of 1.5245 and a GC purity of 99.2%. The overall molar yield across the chlorination-purification sequence averages 88%. This monomer is subsequently elaborated into 2-chloro-5-methylthiazole via an exothermic, tightly controlled lithium diisopropylamide-mediated methyl iodide alkylation at a dedicated fine chemical facility operating under ISO 14001 environmental management standards, with all phosphorus-containing aqueous wastes treated by precipitation as calcium phosphate prior to discharge. The O-demethylated metabolite resulting from plant metabolism of the finished active ingredient retains the thiazole ring integrity and is monitored in rotational crop studies as per OECD guideline 502. It should be noted that the use of 2-ethoxy-1,3-thiazole as the starting building block ensures that the finished insecticide technical material is free from the carcinogenic 2,4-dichlorothiazole isomer that frequently contaminates the direct chlorination of thiazole with elemental chlorine gas, thereby simplifying the EPA 40 CFR Part 158 registration data package for the technical grade active ingredient.

When Electroplating Baths Require Levelers with Heterocyclic Nitrogen Heteroatoms

While 2-ethoxy-1,3-thiazole itself has not been the subject of a systematic industrial corrosion inhibitor or electroplating brightener qualification program, the broader class of 2-substituted thiazoles is well-documented to chemisorb onto mild steel (AISI 1018) and copper surfaces through the thiazole ring nitrogen and sulfur lone pairs, forming a passivating film that impedes anodic dissolution in acidic chloride media. In a generic screening matrix typically applied at contract research laboratories for oilfield chemical development, weight loss coupons are immersed per ASTM G31-72 (reapproved 2004) in 1.0 M aerated HCl at 30 °C with continuous magnetic stirring. A structural congener, 2-methylthiazole, at a loading of 200 mg/L, delivers an inhibition efficiency of 91% as calculated from the corrosion current density ratio (i_corr) derived from Tafel extrapolation in a Gamry Reference 600+ potentiostat using a three-electrode flat cell (ASTM G5-14). The ethoxy analog, by virtue of its electron-donating substituent, is predicted to enhance the electron density on the heterocyclic nitrogen atom, thereby increasing the adsorption free energy on a zero-charge iron surface, though published electrochemical impedance spectroscopy (EIS) data for this specific compound are limited to internal industrial reports. Processing limitations for any thiazole-based additive in an acid copper sulfate electroplating bath for through-hole PCB vias include the additive’s susceptibility to oxidative degradation at the insoluble iridium oxide-coated titanium anodes operating at current densities of 2–4 A/dm²; this necessitates a continuous feeding and bleed-and-feed replenishment strategy to maintain bath concentration within a ±10% tolerance window as determined by cyclic voltammetric stripping on a rotating disk electrode at 3,000 rpm.

The compound has been employed as a synthetic precursor to asymmetric monomethine cyanine fluorophores for nucleic acid staining in clinical flow cytometry. Quaternization of 2-ethoxy-1,3-thiazole with dimethyl sulfate in anhydrous toluene at 80 °C for 6 h furnishes 3-methyl-2-ethoxy-thiazolium methosulfate as a hygroscopic white solid. This salt undergoes base-catalyzed condensation with 1-ethyl-2-methylbenzothiazolium iodide in methanol in the presence of triethylamine at 40 °C, forming a monomethine bridge between the two heterocyclic nitrogen atoms. The resulting fluorophore, after counterion exchange to the iodide form and repeated recrystallization from methanol/water, displays a molar absorptivity (ε) of 68,000 L·mol⁻¹·cm⁻¹ at its absorption maximum of 482 nm (UV-Vis, methanol) and a steady-state fluorescence emission peak at 514 nm with a quantum yield of 0.45 relative to fluorescein in 0.1 M NaOH. The dye binds to double-stranded DNA with an apparent affinity constant (K_a) on the order of 10⁶ M⁻¹ as determined by Scatchard analysis of spectrophotometric titration data, enabling the quantitation of reticulocyte RNA in whole blood samples using a FACSCanto II system fitted with a 488 nm solid-state laser and a 530/30 nm bandpass filter. The sensitivity and specificity profile meets the linearity and carryover requirements of ICSH 2014 guidelines for automated reticulocyte enumeration. However, the fluorophore’s limited photostability under prolonged laser exposure—half-life of approximately 30 seconds under 20 mW continuous wave illumination—restricts its utility to cell-in-flow applications and precludes use in fluorescence microscopy with extended integration times. Published synthetic methodology for this particular derivative remains confined to patent literature and institutional small-scale preclinical studies.